Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: Preliminary results from the CONFIRM-1 trial

Clinical Colorectal Cancer

Volumn 5, Issue 1, 2005, Pages 24-26

  Tyagi, Preeta ^a   Chu, Edward ^a   Jain, Vinay K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB; VATALANIB; ANTINEOPLASTIC AGENT; FOLFOX PROTOCOL; PHTHALAZINE DERIVATIVE; PLATINUM COMPLEX; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DYSPHASIA; FATIGUE; HEADACHE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; SENSORY NEUROPATHY; VOMITING; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; TREATMENT OUTCOME;

EID: 21844464600     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70162-1     Document Type: Article

References (13)

1. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175:409-416.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
3. Dazzi C, Cariello A, Maioli P, et al. Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. Lung Cancer 1999; 24:81-88.
4. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132:541-546.
5. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
7. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000; 60:4819-4824.
8. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PM787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21:3955-3964.
9. Trarbach T, Thomas AL, Bartel C, et al. preliminary phase I results of the oral, once-daily angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with chemotherapy for the treatment of metastatic colorectal cancer. Eur J Cancer 2003; 1 (suppl 5):S91 (Abstract #297).
10. Steward WP, Thomas A, Morgan B, et al. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004; 23:259 (Abstract #3556).
11. First-line treatment of metastatic colorectal cancer with oxaliplatin/ 5-FU/leucovorin plus PTK787/ZK 222584 or placebo. Available at: http://www.clinicaltrials.gov/ct/show/NCT00056459?order=1. Accessed March 31, 2005.
12. Treatment of patients with previously treated metastatic colorectal cancer with oxaliplatin/5FU/LV and PTK787 or placebo. Available at: http://www.clinicaltrials.gov/ct/show/NCT00056446?order=1. Accessed March 31, 2005.
13. PTK/ZK CONFIRM 1 phase III study shows positive drug effects in metastatic colorectal cancer-filing now anticipated for early 2007 [press release]. Berlin: Schering Group; March 21, 2005.